Key result
The evidence base for antithrombotic management in patients with atrial fibrillation and stable vascular disease is less clear than for those presenting with acute coronary syndrome.
Why the study?
The evidence base for managing patients with both atrial fibrillation and stable vascular disease is less clear compared to acute presentations.
The evidence base for antithrombotic management in patients with atrial fibrillation and stable vascular disease is less clear compared to those presenting with acute coronary syndrome or undergoing percutaneous coronary intervention.
Evidence gap leaves antithrombotic strategy undefined in AF with stable vascular disease; dedicated RCTs needed before practice guidance.
Patients with atrial fibrillation are at high risk for stroke, and international guidelines recommend oral anticoagulant therapy. In patients with stable vascular disease without atrial fibrillation, antiplatelet therapy is recommended. However, atrial fibrillation commonly coexists with vascular diseases, such as coronary artery disease. When patients with both conditions present with an acute coronary syndrome or need to undergo percutaneous coronary intervention for implantation of a stent, management with oral anticoagulant therapy plus antiplatelet therapy is clearly supported by evidence from randomized trials. However, the evidence base is less clear for patients with atrial fibrillation and stable vascular disease. The clinician . . .
No takes yet. Share an insight, caveat, or question.
Gregory Y.H. Lip (2024) conducted a review in Atrial fibrillation and stable coronary artery disease. The evidence base for antithrombotic management in patients with atrial fibrillation and stable vascular disease is less clear than for those presenting with acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: